IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.5512
-0.0418 (-7.05%)
At close: Feb 5, 2026, 4:00 PM EST
0.5501
-0.0011 (-0.20%)
After-hours: Feb 5, 2026, 6:29 PM EST
IceCure Medical Revenue
IceCure Medical had revenue of $850.00K in the quarter ending September 30, 2025, with 28.40% growth. This brings the company's revenue in the last twelve months to $2.98M, down -18.96% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$2.98M
Revenue Growth
-18.96%
P/S Ratio
11.85
Revenue / Employee
$45,076
Employees
66
Market Cap
38.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.24M | 137.74% |
| Dec 31, 2019 | 1.63M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TELA Bio | 77.06M |
| Myomo | 41.64M |
| Cytosorbents | 36.98M |
| Baird Medical Investment Holdings | 31.86M |
| electroCore | 29.84M |
| Spectral AI | 23.17M |
| Elutia | 21.75M |
| NeuroOne Medical Technologies | 12.10M |
ICCM News
- 8 days ago - IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer - PRNewsWire
- 24 days ago - IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales - PRNewsWire
- 7 weeks ago - IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer - PRNewsWire
- 2 months ago - IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting - PRNewsWire
- 2 months ago - IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - PRNewsWire
- 2 months ago - IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - PRNewsWire
- 2 months ago - IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - PRNewsWire